[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
The investigation involved 50 patients (fludarabin+cyclophosphamide+prednisolone (FCP)--30; fludarabin+mitoxanthrone+prednisolone (FMP)--17; fludarabin+cyclophosphamide--3). FMP proved the most effective (60%). Yet, FCP results were clinically significant (29%). The efficacy of all the procedures was determined by morphological pattern and was reported in low- and intermediategrade non-Hodgkin's disease alone. Insignificant differences in partial remission duration and stabilization were observed between FMP and FCP, e.g. FMP's effect lasted 1 month longer. No complete remissions were reported; tolerance was reasonable. Tentative findings point to the marked efficacy of fludarabin, particularly, in combination with mitoxanthrone, cyclophosphamide and prednisolone for relapse or refractory low- and intermediate-grade non-Hodgkin's disease.